JPRN-jRCT1031230005招募中Unknown
Efficacy of ensitrelvir and nirmatrelvir/ritonavir for COVID-19
Yoshimura Yukihiro0 个研究点目标入组 360 人开始时间: 2023年4月3日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.18 years old or more
- •2.Antigen or PCR test positive for SARS-CoV-2
- •3.0-3 days after symptom onset
- •4.Having risk factors of severe COVID-19
- •5.Written informed consent is obtained
排除标准
- •1.Severe adverse events by ensitrelvir or nirmatrelvir/ritonavir
- •2.Severe kidney failure (eGFR < 30 mL/min)
- •3.Taking contraindicated medications with ensitrelvir or nirmatrelvir/ritonavir
- •4.Regarded as inappropriate by study investigators
研究者
相似试验
招募中
3 期
Comparing the effectiveness of Kaletra/Hydroxychloroquine and Atazanavir/Dolutegravir/Hydroxychloroquine treatment regiments in COVID-19 treatmentCOVID-19.covid-19 virus identifiedU07.1IRCT20210214050350N1Iran University of Medical Sciences60
进行中（未招募）
Unknown
ensitrelvir in patients with SARS-CoV-2 infection; a randomized, open-label, molnupiravir-controlled studyJPRN-jRCTs071230014Mukae Hiroshi150
已完成
3 期
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)Hepatitis CNCT03833362R-Pharm420
招募中
不适用
Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis CJPRN-UMIN000025050Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology500
已完成
2 期
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCOVID-19NCT05567952Pfizer436